Imaging and localization of Cu labeled trastuzumab in Her2/neu overexpressing non-small cell lung cancer xenografts
Paudyal, P.*; Paudyal, B.*; 飯田 靖彦*; 花岡 宏史*; 渡辺 智; 石岡 典子; 渡邉 茂樹; 高柳 恵美*; 吉岡 弘樹*; 織内 昇*; 富永 英之*; 樋口 徹也*; 遠藤 啓吾*
Paudyal, P.*; Paudyal, B.*; Iida, Yasuhiko*; Hanaoka, Hirofumi*; Watanabe, Satoshi; Ishioka, Noriko; Watanabe, Shigeki; Takayanagi, Megumi*; Yoshioka, Hiroki*; Oriuchi, Noboru*; Tominaga, Hideyuki*; Higuchi, Tetsuya*; Endo, Keigo*
Non-small cell lung carcinoma (NSCLC) overexpress Her2/neu gene in approximately 20% of the cases. Trastuzumab a humanized monoclonal antibody targets Her2/neu and inhibits neoplastic cell proliferation and significantly increases survival of patients with advanced metastatic breast cancer. The present study aimed to determine the effect of trastuzumab in Her2/neu expressing NSCLC with Cu labeled trastuzumab using in vivo PET imaging. Imaging of Her2/neu expression was performed with Cu -DOTA- trastuzumab in H2170 tumor bearing mouse with PET. PET studies revealed relatively high accumulation of Cu -DOTA- trastuzumab in the Her2/neu overexpressing H2170 tumor at 48 h post injection. The success of Cu -DOTA- trastuzumab brought an insight to PET imaging of Her2/neu gene expression in NSCLC patients with Cu -DOTA- trastuzumab to define the patients who might be benefited with trastuzumab based therapy.